Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Stock Information for Lucid Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lucid Diagnostics Inc.

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics to Participate in Upcoming Investor Conferences
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.